Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation.

Introduction: The phosphodiesterase type 5 (PDE5) inhibitors are generally well tolerated and effective for treating erectile dysfunction (ED), including in patients with significant comorbidity. Because of this benign safety profile, investigators have used PDE5 inhibitors to treat patients with ED and severe renal disease or those who have received renal transplants.

Aim: To assess safety and efficacy of PDE5 inhibitors in patients receiving dialysis or renal transplants.

Quality of life in patients undergone oncopreventive intravesical treatment for superficial bladder cancer.

Objectives: Adjuvant intravesical therapy after TURB for superficial bladder cancer forces the patients to follow prolonged protocols of treatment. In our study we considered the quality of life of these patients.

Materials And Methods: We created a questionnaire of 52 items in order to analyse free time, working activity, sexual-relational activity, compliance and self esteem of patients undergone intravesical adjuvant therapy.